3Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the dia,mosis, management, and prevention of chronic obstructive pulmo- nary disease. NHLBI/WHO Global Initiative for Chronic Obstructive [,ung Disease (GOLD) Workshop summary [ J ]. Am J Respir Crit Care Meal,2001,163 ( 5 ) : 1256 - 1276.
5Raolo SM, Snrsa T, Tetwahartiala T, et al. MMP-9 as a marker of ilflamnmtion in tracheal epithelial lining fluid (TELF) and inbron- choal veolar fluid (BALF) of COPD horses [ J ]. Equine Vet J,2001 , 33(2) :128 - 136.
6Culpitt SV, Rogers DF, Traves SL, et al. Sputum matrix metallopro- leases: comparison between ?hmic obstructive pulmonary disease and asthma [ J]. Respir Med,2005,99 ( 6 ) :703 - 710.
7Suga M, I,yonaga K, Okammolo T, et al. Characteristic elevation of maltix metalloproleinase activity in idiopathic intevtitia pneumonias [ J ]. Am J Respir Crit Care Med ,2000,162 ( 5 ) : 1949 - 1956.
8Mereer PF, Shute JK, Bhowmik A, et al. MMP-9, TIMP-I and intlammatoL'y eells in sputum from COPD patients during exaeerbatiort [ J]. Respir Res,2005,22( 6 ) : 151 - 160.
9Vignola AM, Riccobono L, Mi,'abella ., et al. Spulum metalloprotei- nase - I ratio correlates with airflow obstruction in asthma and chronic bronchitis[j]. Am J Respir Crit Care Med,2003, 158 (4) : 1945 - 1950.
9Lowrey GE,Henderson N,Blakey JD,et al.MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD[J].Respir Med,2008,102(6):845-851.
10Joos L,He JQ,Shepherdson MB,et al.The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function[J].Hum Mol Genet,2002,11(5):569-576.
